BOOKS BY CATEGORY
Your Account
COX-2 Blockade in Cancer Prevention and Therapy
Price
Quantity
£166.50
(To see other currencies, click on price)
Paperback / softback
Add to basket  

MORE ABOUT THIS BOOK

Main description:

The revelation that aspirin and aspirin-like compounds have notableantineo­ plastic properties has revolutionized cancer research. COX-2 Blockade in Cancer Prevention and Therapy chronicles the evidence and presents exciting new op­ portunities for the use of cyclooxygenase-2 (COX-2) blockade in the prevention and treatment of cancer. The text is divided broadly into five areas. First, an historical overview documents the scientific discovery ofCOX-2 and the pharma­ ceutical development of nonsteroidal anti-inflammatory drugs (NSAIDs) designed for selective COX-2 inhibition. The process by which essential poly­ unsaturated fatty acids (PUF As) stimulate prostaglandin biosynthesis and cancer development, and its interruption by COX-2 inhibition, is elucidated. This is followed by a section on the epidemiology of NSAIDs and cancers of the colon and breast, and other anatomic sites. These chapters reflect significant cancer protection owing to the regular use of common NSAIDs such as aspirin and ibuprofen. A section on animal models of carcinogenesis presents comprehensive evidence that general NSAIDs inhibit a variety of malignant neoplasms in vivo, and highlights recent findings which show that COX-2 blocking agents produce striking chemopreventive effects against colon cancer and breast cancer as well as other malignancies. Genetic models are presented confirming the critical role of COX-2 in carcinogenesis. Section IV then discusses the molecular biology of COX -2 vis-a-vis the role of COX -2 and, to a lesser extent, COX -1, in modulating a number of important processes in molecular carcinogenesis such as mutagen­ esis, cell division, angiogenesis, cell differentiation, and apoptosis.


Back cover:

The discovery that aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) have notable antineoplastic properties has revolutionized cancer research. In COX-2 Blockade in Cancer Prevention and Therapy, a panel of leading experts chronicles the evidence for the chemopreventive and therapeutic effects of cyclooxygenase-2 (COX-2) inhibitors against virtually all forms of cancer and presents exciting new opportunities for the use of COX-2 blockade in their prevention and treatment. These highly experienced authors elucidate the process by which COX-2 inhibitors interrupt prostaglandin biosynthesis and cancer development, examine the positive epidemiological effects of such NSAIDs as aspirin and ibuprofen on various cancers, and demonstrate through animal models that NSAIDs inhibit a variety of malignant neoplasms in vivo. They also present genetic models confirming the critical role of COX-2 in carcinogenesis and discuss how its molecular biology modulates carcinogenesis via such processes as mutagenesis, cell division, angiogenesis, cell differentiation, and apoptosis. In addition, the authors review the clinical applications of selected NSAIDs that are immediately relevant to cancer prevention and control and outline the future prospects of COX-2 blocking agents.

Comprehensive and up-to-date, COX-2 Blockade in Cancer Prevention and Therapy demonstrates how COX-2 inhibitors and other NSAIDs reduce the risk of most cancers and provides cancer investigators today with a clear and authoritative guide to the development of novel agents with significant antineoplastic properties.


Contents:

Part I. Historical Perspectives

Dietary Fatty Acids, COX-2 Blockade, and Carcinogenesis
Rashida A. Karmali

Historical Aspects of COX-2: Cloning and Characterization of the cDNA, Protein and Gene
Harvey R. Herschman

Part II. Epidemiology of NSAIDs and Cancer

Epidemiology of Nonsteroidal Anti-Inflammatory Drugs and Colorectal Cancer
Michael J. Thun and S. Jane Henley

Epidemiology of Breast Cancer and Nonsteroidal Anti-Inflammatory Drugs: Extension of the Dietary Fat Hypothesis of Breast Cancer
Randall E. Harris

Part III. Animal Models of Carcinogenesis

Role of Synthetic and Naturally Occurring Cyclooxygenase Inhibitors in Colon Cancer Prevention
Bandaru S. Reddy and Chinthalapally V. Rao

Chemoprevention of Breast Cancer by Nonsteroidal Anti-Inflammatory Drugs and Selective COX-2 Blockade in Animals
Hussein M. Abou-Issa, Galal A. Alshafie, and Randall E. Harris

The Role of Cyclooxygenase-2 in the Prevention and Therapy of Lung Cancer
Hildegard M. Schuller

Nonsteroidal Anti-Inflammatory Drugs, Prostaglandins, and Apc-Driven Intestinal Tumorigenesis
Jay Whelan and Michael F. McEntee

Cyclooxygenase-1 and Cyclooxygenase-2 Knockout Mice Provide Insights into Beneficial and Adverse Effects of Nonsteroidal Anti-Inflammatory Drugs
Robert Langenbach

Part IV. Molecular Biology of COX-2

Cyclooxygenase-2, Prostaglandins, and Colorectal Carcinogenesis
Rajnish A. Gupta and Raymond N. DuBois

Regulation of Expression and Potential Carcinogenic Role of Cyclooxygenase-2
Byeong-Churl Jang and Timothy Hla

Cyclooxygenase-2 and Cancer
Alane T. Koki, Kathleen M. Leahy, Janet M. Harmon, and Jaime L. Masferrer

Interactions of Cyclooxygenase and Aromatase Pathways in Normal and Malignant Breast Cells
Jeanette A. Richards and Robert W. Brueggemeier

Association of COX-2 and PPARs in Carcinogenesis and Chemoprevention
Tong-Chuan He

Carcinogenesis Involving Cyclooxygenase and Lipoxygenase
Linda C. Hsi and Thomas E. Eling

Part V. Clinical Applications

The Development of Drugs that Target Cyclooxygenase-2
Timothy Maziasz, K. Nasir Khan, John Talley, James Gierse, and Karen Seibert

Chemoprevention of Cancer by NSAIDs and Selective COX-2 Blockade
Gary J. Kelloff, Vernon E. Steele, and Caroline C. Sigman

Potential for Inhibitors of Cyclooxygenase-2 to Enhance Tumor Radioresponse
Randy Burd, Hak Choy, and Adam Dicker

Potential Role of NSAIDs and COX-2 Blockade in Cancer Therapy
William F. Anderson, Asad Umar, Jaye L. Viner, and Ernest T. Hawk

Cyclooxygenase-2 Blockade in Cancer Prevention and Therapy: Widening the Scope of Impact
Randall E. Harris

Index


PRODUCT DETAILS

ISBN-13: 9781617373046
Publisher: Springer (Humana Press)
Publication date: November, 2010
Pages: 384
Weight: 805g
Availability: POD
Subcategories: Oncology
Related books
From the same series

CUSTOMER REVIEWS

Average Rating 

"...a must, not only for oncologists but also for every family doctor, who is often the first to see a patient with a cancerous or precancerous or precancerous condition." -Lancet Oncology

"This comprehensive and up-to-date monograph demonstrates how COX-2 inhibitors and other NSaids reduce the risk of most cancers and provides cancer investigators by a clear and authoritative guide leading to the development of novel angst with significant antineoplastic properties." -Neoplasma